{
  "abstract": "An 81-year-old man with a history of multiple myeloma presented with decompensated heart failure (HF). Although his baseline left ventricular ejection fraction (LVEF) was preserved, it significantly declined to 35% at 13 months after the initiation of ixazomib. Considering the chronological relationship between the timing of ixazomib treatment and symptom onset, prior normal echocardiography, and multimodal imaging findings, ixazomib-induced cancer therapy-related cardiac dysfunction (CTRCD) was strongly suspected. Despite the discontinuation of ixazomib and continued administration of guideline-directed medical therapy, his LVEF has not recovered to date. We herein report a rare case of ixazomib-induced irreversible CTRCD.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "name": "Yusuke Hirao"
    },
    {
      "name": "Kensuke Matsumoto"
    },
    {
      "name": "Yu Mizutani"
    },
    {
      "name": "Shinnosuke Tsukamoto"
    },
    {
      "name": "Akari Odagi"
    },
    {
      "name": "Yuto Shinkura"
    },
    {
      "name": "Ryo Nishio"
    },
    {
      "name": "Masahiko Hoshijima"
    },
    {
      "name": "Satoru Kawasaki"
    },
    {
      "name": "Hogara Nishisaki"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5123syfpxhx6h.bib",
  "cited_by": 1,
  "doi": "10.2169/internalmedicine.6894-25",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6894-25/_article",
  "id": "5123syfpxhx6h",
  "issns": [
    "1349-7235",
    "0918-2918"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6894-25/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/general"
    ],
    [
      "openalex",
      "2705|Chemotherapy-induced cardiotoxicity and mitigation"
    ]
  ],
  "openalex": "W7131062622",
  "pdf_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6894-25/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/5123syfpxhx6h.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "10.2169/internalmedicine.6894-25",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6894-25/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2705|Chemotherapy-induced cardiotoxicity and mitigation",
      "subfield": "cardiovascular"
    }
  ],
  "title": "\"Et tu, Brute?\" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction",
  "title_text": "\"Et tu, Brute?\" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/5123syfpxhx6h",
  "venue": "Internal Medicine",
  "versions": []
}